Neue S3-Leitlinie Prostatakarzinom 2021 (Version 6.2) – Was hat sich beim fortgeschrittenen Prostatakarzinom geändert?

There have been numerous new findings from clinical trials in recent years regarding the treatment of metastatic hormone-sensitive or castration-resistant prostate cancer. The newly approved treatment options make therapy planning and therapy sequencing more challenging. In addition, local therapy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, C., Schrader, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
Übersichten
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911494/
https://www.ncbi.nlm.nih.gov/pubmed/36066611
http://dx.doi.org/10.1007/s00120-022-01927-z
Descripción
Sumario:There have been numerous new findings from clinical trials in recent years regarding the treatment of metastatic hormone-sensitive or castration-resistant prostate cancer. The newly approved treatment options make therapy planning and therapy sequencing more challenging. In addition, local therapy of metastatic prostate cancer is becoming increasingly important. In the new German guidelines on prostate cancer (version 6.2, October 2021), new developments in the recommendations for the treatment of mHSPC and mCRPC were implemented, and their most important resulting recommendations for the clinical practice are presented in this review.

Ejemplares similares